{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T06:05:24Z","timestamp":1791439524472,"version":"4.3.3"},"reference-count":29,"publisher":"BMJ","license":[{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"National Institute for Health and Care Research Health Technology Assessment Programme","award":["15\/100\/01"],"award-info":[{"award-number":["15\/100\/01"]}]},{"name":"Belfast Health and Social Care Trust Charitable Funds","award":["no award\/grant number"],"award-info":[{"award-number":["no award\/grant number"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Thorax"],"accepted":{"date-parts":[[2026,7,20]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Lung function measurement is central to assessing disease severity and monitoring progression in bronchiectasis. Although home spirometry is convenient for remote monitoring, there is limited evidence for its performance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>In an a priori defined substudy in the CLEAR trial (a multicentre, randomised, open-label study of hypertonic saline and carbocisteine versus usual care in bronchiectasis), we assessed the performance of home spirometry in adults with bronchiectasis using the PANACEA framework (seven domains: test Performance, disease mANAgement, Cost, patient Experience, clinician Experience, researcher Experience, and Access).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Participants performed supervised \u2018clinic\u2019 spirometry at five visits and unsupervised \u2018home\u2019 spirometry weekly and during exacerbations over 52 weeks. Analyses evaluated agreement, longitudinal variation, changes in lung function across exacerbations, measurement quality, adherence and patient experience. Agreement was evaluated using Bland-Altman analysis; other outcomes were summarised descriptively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      257 participants had home spirometry data. Clinic and home spirometry demonstrated close agreement, with a mean forced expiratory volume in 1 s (FEV\n                      <jats:sub>1<\/jats:sub>\n                      ) difference of 20 mL (95% CI \u2212130 to 170). Variability decreased over time (coefficient of variation 12.25% to 8.81%). Among 462 exacerbations, 195 had spirometry data within 7 days of exacerbation start\/end dates. A &gt;100\u2009mL decline in FEV\n                      <jats:sub>1<\/jats:sub>\n                      occurred in 48% of exacerbations; 35% returned to within 100 mL of pre-exacerbation stable values by exacerbation end. Most spirometry sessions met American Thoracic Society\/European Respiratory Society quality criteria, adherence declined over time while patient experience was generally positive.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Home spirometry demonstrates good agreement with clinic spirometry, with variability between measurements decreasing over time. Home spirometry detected changes in lung function across exacerbations, although variability may limit interpretation at the individual patient level. With appropriate patient support to maintain adherence, home spirometry has potential as a tool for remote monitoring and decentralised clinical trials in bronchiectasis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"isrctn\" xlink:href=\"ISRCTN89040295\">ISRCTN89040295<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/thorax-2026-225189","type":"journal-article","created":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T17:20:26Z","timestamp":1785950426000},"page":"thorax-2026-225189","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Unsupervised home spirometry versus supervised clinic spirometry: analysis of longitudinal participant-level data from the CLEAR trial in patients with bronchiectasis"],"prefix":"10.1136","clinical-trial-number":[{"clinical-trial-number":"isrctn89040295","registry":"10.18810\/isrctn"}],"author":[{"given":"Ryan","family":"McChrystal","sequence":"first","affiliation":[{"name":"Wellcome Trust-Wolfson Northern Ireland Clinical Research Facility, Queen\u2019s University Belfast, Belfast, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0647-2503","authenticated-orcid":false,"given":"Rebecca H","family":"McLeese","sequence":"additional","affiliation":[{"name":"Wellcome Trust-Wolfson Northern Ireland Clinical Research Facility, Queen\u2019s University Belfast, Belfast, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6471-1413","authenticated-orcid":false,"given":"Brenda","family":"O\u2019Neill","sequence":"additional","affiliation":[{"name":"Ulster University, Coleraine, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3283-1947","authenticated-orcid":false,"given":"Daniel F","family":"McAuley","sequence":"additional","affiliation":[{"name":"Wellcome-Wolfson Institute for Experimental Medicine, Queen\u2019s University Belfast, Belfast, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J Stuart","family":"Elborn","sequence":"additional","affiliation":[{"name":"Wellcome-Wolfson Institute for Experimental Medicine, Queen\u2019s University Belfast, Belfast, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2926-7257","authenticated-orcid":false,"given":"Mike","family":"Clarke","sequence":"additional","affiliation":[{"name":"Centre for Public Health, Queen\u2019s University Belfast, Belfast, UK"},{"name":"Northern Ireland Clinical Trials Unit, Belfast, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Norrie","sequence":"additional","affiliation":[{"name":"Centre for Public Health, Queen\u2019s University Belfast, Belfast, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0552-1115","authenticated-orcid":false,"given":"Dermot","family":"Linden","sequence":"additional","affiliation":[{"name":"Wellcome-Wolfson Institute for Experimental Medicine, Queen\u2019s University Belfast, Belfast, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Stewart","sequence":"additional","affiliation":[{"name":"Wellcome-Wolfson Institute for Experimental Medicine, Queen\u2019s University Belfast, Belfast, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Jackson","sequence":"additional","affiliation":[{"name":"Northern Ireland Clinical Trials Unit, Belfast, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3782-659X","authenticated-orcid":false,"given":"William D-C","family":"Man","sequence":"additional","affiliation":[{"name":"Royal Brompton and Harefield Hospitals, Guy's and St. Thomas' NHS Foundation Trust, London, UK"},{"name":"Faculty of Life Sciences and Medicine, King's College London, London, UK"},{"name":"National Heart and Lung Institute, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"De Soyza","sequence":"additional","affiliation":[{"name":"Population Health Sciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5514-7868","authenticated-orcid":false,"given":"James D","family":"Chalmers","sequence":"additional","affiliation":[{"name":"Scottish Centre for Respiratory Research, University of Dundee, Ninewells Hospital and Medical School, Dundee, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1957-5336","authenticated-orcid":false,"given":"Rohan","family":"Anand","sequence":"additional","affiliation":[{"name":"Wellcome-Wolfson Institute for Experimental Medicine, Queen\u2019s University Belfast, Belfast, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Copeland","sequence":"additional","affiliation":[{"name":"Primary Ciliary Dyskinesia Family Support Group, Ciliopathy Alliance, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judy M","family":"Bradley","sequence":"additional","affiliation":[{"name":"Wellcome Trust-Wolfson Northern Ireland Clinical Research Facility, Queen\u2019s University Belfast, Belfast, UK"},{"name":"Wellcome-Wolfson Institute for Experimental Medicine, Queen\u2019s University Belfast, Belfast, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,8,5]]},"reference":[{"key":"2026080510202172000_thorax-2026-225189v1.1","doi-asserted-by":"crossref","DOI":"10.1136\/thx.2010.142778","article-title":"British Thoracic Society guideline for non-CF bronchiectasis","volume":"65","author":"Pasteur","year":"2010","journal-title":"Thorax"},{"key":"2026080510202172000_thorax-2026-225189v1.2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201309-1575OC"},{"key":"2026080510202172000_thorax-2026-225189v1.3","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00026313"},{"key":"2026080510202172000_thorax-2026-225189v1.4","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1513\/AnnalsATS.202206-493OC","article-title":"Clinimetric Properties of Outcome Measures in Bronchiectasis","volume":"20","author":"Bradley","year":"2023","journal-title":"Ann Am Thorac Soc"},{"key":"2026080510202172000_thorax-2026-225189v1.5","unstructured":"U.S. Food and Drug Administration . Table of surrogate endpoints that were the basis of drug approval or licensure. 2025. Available: https:\/\/www.fda.gov\/drugs\/development-resources\/table-surrogate-endpoints-were-basis-drug-approval-or-licensure"},{"key":"2026080510202172000_thorax-2026-225189v1.6","unstructured":"European Medicines Agency . Committee for medicinal products for human use (CHMP) guideline on clinical development of medicinal products for the treatment of cystic fibrosis doc. ref. emea\/chmp\/ewp\/9147\/2008. 2008."},{"key":"2026080510202172000_thorax-2026-225189v1.7","doi-asserted-by":"publisher","DOI":"10.1183\/20734735.0021711"},{"key":"2026080510202172000_thorax-2026-225189v1.8","doi-asserted-by":"crossref","DOI":"10.12688\/gatesopenres.13146.1","article-title":"Clinical trials in the pandemic age: What is fit for purpose?","volume":"4","author":"Hartman","year":"2020","journal-title":"Gates Open Res"},{"key":"2026080510202172000_thorax-2026-225189v1.9","doi-asserted-by":"crossref","DOI":"10.1136\/bmjhci-2020-100302","article-title":"Strengthening healthcare delivery with remote patient monitoring in the time of COVID-19","volume":"28","author":"Mantena","year":"2021","journal-title":"BMJ Health Care Inform"},{"key":"2026080510202172000_thorax-2026-225189v1.10","unstructured":"Madge S , Parrott H . Remote monitoring and virtual clinic for patients with respiratory conditions. NHS England \u2013 Transformation Directorate; 2021."},{"key":"2026080510202172000_thorax-2026-225189v1.11","doi-asserted-by":"publisher","DOI":"10.1378\/chest.117.1.148"},{"key":"2026080510202172000_thorax-2026-225189v1.12","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1089\/tmj.2017.0160","article-title":"Advances in Remote Respiratory Assessments for People with Chronic Obstructive Pulmonary Disease: A Systematic Review","volume":"24","author":"Baroi","year":"2018","journal-title":"Telemed J E Health"},{"key":"2026080510202172000_thorax-2026-225189v1.13","doi-asserted-by":"crossref","DOI":"10.2196\/16158","article-title":"Use of the patientMpower App With Home-Based Spirometry to Monitor the Symptoms and Impact of Fibrotic Lung Conditions: Longitudinal Observational Study","volume":"8","author":"Edwards","year":"2020","journal-title":"JMIR Mhealth Uhealth"},{"key":"2026080510202172000_thorax-2026-225189v1.14","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S106142"},{"key":"2026080510202172000_thorax-2026-225189v1.15","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/cts.12901","article-title":"Remote FEV1 Monitoring in Asthma Patients: A Pilot Study","volume":"14","author":"Huang","year":"2021","journal-title":"Clin Transl Sci"},{"key":"2026080510202172000_thorax-2026-225189v1.16","doi-asserted-by":"crossref","DOI":"10.1186\/s12931-020-01524-8","article-title":"Variability of forced vital capacity in progressive interstitial lung disease: a prospective observational study","volume":"21","author":"Veit","year":"2020","journal-title":"Respir Res"},{"key":"2026080510202172000_thorax-2026-225189v1.17","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02406-2016","article-title":"Home monitoring improves endpoint efficiency in idiopathic pulmonary fibrosis","volume":"50","author":"Johannson","year":"2017","journal-title":"Eur Respir J"},{"key":"2026080510202172000_thorax-2026-225189v1.18","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202410-2080ST"},{"key":"2026080510202172000_thorax-2026-225189v1.19","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0248-2022","article-title":"Unsupervised home spirometry versus supervised clinic spirometry for respiratory disease: a systematic methodology review and meta-analysis","volume":"32","author":"Anand","year":"2023","journal-title":"Eur Respir Rev"},{"key":"2026080510202172000_thorax-2026-225189v1.20","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJMoa2510095","article-title":"Hypertonic Saline or Carbocisteine in Bronchiectasis","volume":"393","author":"Bradley","year":"2025","journal-title":"N Engl J Med"},{"key":"2026080510202172000_thorax-2026-225189v1.21","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00051-2017","article-title":"Pulmonary exacerbation in adults with bronchiectasis: a consensus definition for clinical research","volume":"49","author":"Hill","year":"2017","journal-title":"Eur Respir J"},{"key":"2026080510202172000_thorax-2026-225189v1.22","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00080312"},{"key":"2026080510202172000_thorax-2026-225189v1.23","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201908-1590ST"},{"key":"2026080510202172000_thorax-2026-225189v1.24","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01499-2021","article-title":"ERS\/ATS technical standard on interpretive strategies for routine lung function tests","volume":"60","author":"Stanojevic","year":"2022","journal-title":"Eur Respir J"},{"key":"2026080510202172000_thorax-2026-225189v1.25","doi-asserted-by":"crossref","DOI":"10.2196\/60892","article-title":"Accuracy, Reproducibility, and Responsiveness to Treatment of Home Spirometry in Cystic Fibrosis: Multicenter, Retrospective, Observational Study","volume":"26","author":"Oppelaar","year":"2024","journal-title":"J Med Internet Res"},{"key":"2026080510202172000_thorax-2026-225189v1.26","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jcf.2021.08.013","article-title":"A comparison of clinic and home spirometry as longitudinal outcomes in cystic fibrosis","volume":"21","author":"Paynter","year":"2022","journal-title":"J Cyst Fibros"},{"key":"2026080510202172000_thorax-2026-225189v1.27","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1002\/ppul.26147","article-title":"Real-world feasibility of short-term, unsupervised home spirometry in CF","volume":"57","author":"Davis","year":"2022","journal-title":"Pediatr Pulmonol"},{"key":"2026080510202172000_thorax-2026-225189v1.28","doi-asserted-by":"crossref","DOI":"10.1136\/bmjresp-2023-001837","article-title":"Patient perspectives on home-spirometry in interstitial lung disease: a qualitative co-designed study","volume":"10","author":"Mandizha","year":"2023","journal-title":"BMJ Open Respir Res"},{"key":"2026080510202172000_thorax-2026-225189v1.29","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-019-3766-9","article-title":"A 2 \u00d7 2 factorial, randomised, open-label trial to determine the clinical and cost-effectiveness of hypertonic saline (HTS 6%) and carbocisteine for airway clearance versus usual care over 52\u2009weeks in adults with bronchiectasis: a protocol for the CLEAR clinical trial","volume":"20","author":"Bradley","year":"2019","journal-title":"Trials"}],"container-title":["Thorax"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/thorax-2026-225189","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T17:20:29Z","timestamp":1785950429000},"score":1,"resource":{"primary":{"URL":"https:\/\/thorax.bmj.com\/lookup\/doi\/10.1136\/thorax-2026-225189"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,5]]},"references-count":29,"alternative-id":["10.1136\/thorax-2026-225189"],"URL":"https:\/\/doi.org\/10.1136\/thorax-2026-225189","relation":{},"ISSN":["0040-6376","1468-3296"],"issn-type":[{"value":"0040-6376","type":"print"},{"value":"1468-3296","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,5]]}}}